Target intelligence / Profile preview

Homeobox protein Nkx-2.5 (NKX2-5)

Target
NKX2-5
Molecular classification
Transcription factor, Homeodomain protein, Cardiac kernel transcription factor
01

Overview

Homeobox protein Nkx-2.5 (NKX2-5) is a highly conserved transcription factor that plays a critical role in heart development and function. It belongs to the NK-2 class of homeodomain proteins and acts as a key component of the "cardiac kernel," a group of transcription factors essential for the specification, proliferation, and differentiation of cardiac precursor cells into mature cardiomyocytes. NKX2-5 initiates the cardiac gene program early in embryogenesis and regulates genes involved in cardiac morphogenesis, chamber formation, and the conduction system. Mutations in NKX2-5 are a common cause of inherited congenital heart disease, particularly atrial septal defects and conduction disorders. While essential for cardiac development, there are currently no drugs that directly target NKX2-5, as its modulation carries significant risks due to its central role in maintaining cardiac structure and function.

Other names
CsxNKX2.5NKX2ECSX1NKX4-1Cardiac-specific homeoboxHomeobox protein CSXHomeobox protein NK-2 homolog Etinman homologtinman paralogCHNG5HLHS2VSD3cardiac-specific homeobox 1
02

Mechanism of action

No direct drug mechanism known; gene mutations underpin disease rather than pharmacological modulation

03

Biological functions

Cardiac developmentCardiac precursor cell differentiationCardiac morphogenesisAtrial, ventricular, and conduction system formationRegulation of gene expression in heart tissueCell proliferation (cardiac context)Cell fate determination (cardiac precursor cells)
04

Disease associations

Cardiovascular diseaseCongenital heart diseaseArrhythmia and conduction system disorders
05

Safety considerations

Targeting NKX2-5 could disrupt essential cardiac developmental pathways and conduction, presenting major safety risks if modulated in non-therapeutic contexts
06

Interacting drugs

No approved small-molecule or biologic therapies directly target NKX2-5 in current clinical use; no interacting drugs
07

Biomarkers

NKX2-5 gene mutations as genetic biomarkers for congenital heart disease (e.g., atrial septal defect, conduction system disease)

Beyond the preview

Go deeper on Homeobox protein Nkx-2.5 (NKX2-5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Homeobox protein Nkx-2.5 (NKX2-5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call